Therapies for Treatment-Resistant Depression

Nearly all pharmacological treatments for depression and treatment-resistant depression (TRD), have been based on the monoamine hypothesis of depression and on established first-line antidepressant medications that function to increase the availability of serotonin and/or other monoamine neurotransmitters. In the last few years, the first non-monoaminergic agent, esketamine, gained regulatory approval for the treatment of adults with TRD as well as other forms of treatment options. Therapies for Treatment-Resistant Depression: Neuropharmacology and Neurostimulation provides readers with an authoritative, comprehensive and targeted treatment guide. The first section reviews the essential knowledge and methods of clinical neuroscience and neuropsychopharmacological techniques as they apply to novel treatment discovery for depression. This is followed by detailed chapters on ketamine, esketamine, other glutamate modulators in development, GABA modulators, neuropeptides, anti-inflammatory agents, and other classes of novel therapeutics under study for TRD and related mood disorders. The last section consists of a set of chapters of special interest that includes current and future research directions, development of psilocybin-based interventions and other psychedelic compounds currently under study for TRD and advances in biomarker-guided and personalized treatment. Edited by world renowned experts in the field this book is the ultimate resource for researchers and clinicians.